INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 451m ago
HOUSE PTR50m ago
SEC 13F50m ago
ROBINHOOD CHAIN50m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Karas Eric reported SPRY

Chief Commercial Officer · ARS Pharmaceuticals, Inc. · ARS Pharmaceuticals, Inc. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
25.0K
Price
—
Executed
Jun 12, 2026
Disclosed
Jun 12, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jun 12 executedJun 12, 2026 disclosed

SPRY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
3/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 5.1% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SPRY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SL
    Slebir John LChief Legal Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.20M sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CD
    Casale DonnDirector, President and CEO
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.04M sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SE
    Smith Margaret EkinsChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.00M sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CD
    Casale DonnPresident
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    898.5K sh
    		Jul 1, 2026Jul 2, 2026
    traded Jul 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KM
    Kelly MichaelDirector
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    30.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    23
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    11
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$38K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    21
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise
    		M—
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    42
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$1.21M
    136.4K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    31
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$267K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    17
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise
    		M$25K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001951287-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 12, 2026
    Published
    Jun 12, 2026
    Ingested by INSIDER
    Nov 5, 03:53 UTC
    Last re-read
    Nov 5, 03:53 UTC

    Extracted facts

    Filer
    Karas Eric
    Role
    Chief Commercial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    ARS Pharmaceuticals, Inc. — Stock Option (Right to Buy)
    Ticker
    SPRY
    Shares
    25.0K
    Price per share
    $0
    Execution date (reported)
    Jun 12, 2026
    Owned after transaction
    519.6K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    0

    What this establishes

    Karas Eric filed this Form 4 reporting a option exercise of SPRY on Jun 12, 2026. It became public on Jun 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Karas Ericcik:0001951287
    Issuer
    ARS Pharmaceuticals, Inc.cik:0001671858

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.